- Report
- September 2024
- 343 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- March 2023
- 147 Pages
Global
From €4691EUR$4,949USD£3,919GBP
- Report
- January 2024
- 156 Pages
United States
€3602EUR$3,800USD£3,009GBP
- Report
- January 2024
- 114 Pages
United States
€3317EUR$3,500USD£2,771GBP
- Report
- January 2024
- 109 Pages
United States
€3317EUR$3,500USD£2,771GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
Xopenex (levosalbutamol) is a prescription medication used to treat and prevent symptoms of airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it works by relaxing the muscles in the airways, allowing more air to flow in and out of the lungs. Xopenex is a brand name for levalbuterol, a short-acting beta-2 agonist (SABA). It is available in both an inhalation solution and an inhalation aerosol.
Xopenex is used to treat and prevent symptoms of airway diseases, such as wheezing, chest tightness, and shortness of breath. It is also used to prevent exercise-induced bronchospasm. Xopenex is typically used in combination with other medications, such as inhaled corticosteroids, to treat and prevent symptoms of airway diseases.
The Xopenex market is a subset of the larger respiratory drugs market. It is composed of companies that manufacture and distribute Xopenex and related products. These companies include Sunovion Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, and Hikma Pharmaceuticals. Show Less Read more